Should vascular effects of newer treatments be addressed more completely?

Eric H. Yang, Karol E. Watson, Joerg Herrmann

Research output: Contribution to journalReview article

7 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)1995-1998
Number of pages4
JournalFuture Oncology
Volume11
Issue number14
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pyridazines
bcr-abl Fusion Proteins
Imidazoles
Peripheral Arterial Disease
Protein Kinase Inhibitors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Antineoplastic Agents
Blood Vessels
Leukemia
Cardiovascular Diseases
Dasatinib
ponatinib
Cardiotoxicity
Imatinib Mesylate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

Keywords

  • cardio-oncology
  • cardiotoxicity
  • dasatinib
  • imatinib resistance
  • leukemia
  • nilotinib
  • peripheral arterial disease
  • ponatinib
  • tyrosine kinase inhibitors
  • vascular toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Should vascular effects of newer treatments be addressed more completely? / Yang, Eric H.; Watson, Karol E.; Herrmann, Joerg.

In: Future Oncology, Vol. 11, No. 14, 01.01.2015, p. 1995-1998.

Research output: Contribution to journalReview article

Yang, Eric H. ; Watson, Karol E. ; Herrmann, Joerg. / Should vascular effects of newer treatments be addressed more completely?. In: Future Oncology. 2015 ; Vol. 11, No. 14. pp. 1995-1998.
@article{e7a0f6458e9346dca34ef9caf0665146,
title = "Should vascular effects of newer treatments be addressed more completely?",
keywords = "cardio-oncology, cardiotoxicity, dasatinib, imatinib resistance, leukemia, nilotinib, peripheral arterial disease, ponatinib, tyrosine kinase inhibitors, vascular toxicity",
author = "Yang, {Eric H.} and Watson, {Karol E.} and Joerg Herrmann",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/fon.15.119",
language = "English (US)",
volume = "11",
pages = "1995--1998",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Should vascular effects of newer treatments be addressed more completely?

AU - Yang, Eric H.

AU - Watson, Karol E.

AU - Herrmann, Joerg

PY - 2015/1/1

Y1 - 2015/1/1

KW - cardio-oncology

KW - cardiotoxicity

KW - dasatinib

KW - imatinib resistance

KW - leukemia

KW - nilotinib

KW - peripheral arterial disease

KW - ponatinib

KW - tyrosine kinase inhibitors

KW - vascular toxicity

UR - http://www.scopus.com/inward/record.url?scp=84937794972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937794972&partnerID=8YFLogxK

U2 - 10.2217/fon.15.119

DO - 10.2217/fon.15.119

M3 - Review article

C2 - 26198824

AN - SCOPUS:84937794972

VL - 11

SP - 1995

EP - 1998

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -